Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

T1810000

Tranexamic acid

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

trans-4-(Aminomethyl)cyclohexanecarboxylic acid, AMCA, AMCHA, HAKU, TAMCHA, Tranexamic acid

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula linear:
H2NCH2C6H10CO2H
Número CAS:
1197-18-8
Peso molecular:
157.21
Beilstein:
2207452
Número MDL:
MFCD00001466
Código UNSPSC:
41116107
ID de substância PubChem:
329826687
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

tranexamic acid

fabricante/nome comercial

EDQM

pf

>300 °C (lit.)

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

NC[C@H]1CC[C@@H](CC1)C(O)=O

InChI

1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-

chave InChI

GYDJEQRTZSCIOI-LJGSYFOKSA-N

Informações sobre genes

human ... PLG(5340)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Tranexamic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

Pictogramas

Exclamation mark
GHS07

Palavra indicadora

Warning

Frases de perigo

H315,H319,H335

Declarações de precaução

P302 + P352 - P305 + P351 + P338

Classificações de perigo

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Órgãos-alvo

Respiratory system

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Choose from one of the most recent versions:

Certificados de análise (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 3

1 of 3

Tissue plasminogen activator human

Sigma-Aldrich

T0831

Tissue plasminogen activator human

Sigma-Aldrich

Sigma-Aldrich

605190-M

Thrombin, Human Plasma

N-Succinyl-Ala-Ala-Ala-p-nitroanilide elastase substrate

Sigma-Aldrich

S4760

N-Succinyl-Ala-Ala-Ala-p-nitroanilide

Sattar Alshryda et al.
The Journal of bone and joint surgery. American volume, 95(21), 1969-1974 (2013-11-08)
Approximately one-third of patients undergoing total hip replacement surgery require one to three units of blood postoperatively. Tranexamic acid is a synthetic antifibrinolytic agent that has been successfully used intravenously to control bleeding after total hip replacement. A topical application
Sattar Alshryda et al.
The Journal of bone and joint surgery. American volume, 95(21), 1961-1968 (2013-11-08)
Approximately one-third of patients undergoing total knee replacement require one to three units of blood postoperatively. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that has been successfully used intravenously to stop bleeding after total knee replacement. A topical application
S Grassin-Delyle et al.
British journal of anaesthesia, 111(6), 916-924 (2013-07-25)
Interest in antifibrinolytic tranexamic acid (TA) has grown since the widespread removal of aprotinin, but its dosing during cardiac surgery is still debated. The objectives of this study were to investigate the population pharmacokinetics (PK) of TA given with either
Kristen A Matteson et al.
Obstetrics and gynecology, 121(3), 632-643 (2013-05-03)
To compare the effectiveness of nonsurgical abnormal uterine bleeding treatments for bleeding control, quality of life (QOL), pain, sexual health, patient satisfaction, additional treatments needed, and adverse events. MEDLINE, Cochrane databases, and Clinicaltrials.gov were searched from inception to May 2012.
Case scenario: management of trauma-induced coagulopathy in a severe blunt trauma patient.
Jean-Stephane David et al.
Anesthesiology, 119(1), 191-200 (2013-03-22)
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica